Mesosil, a cutting-edge research startup focusing on the commercialization of intellectual property developed at the University of Toronto in the Medical and Dental Devices sector for infection treatment and disease prediction, has successfully raised $2,200,000 in funding. The company plans to utilize this capital injection to further advance its research and development efforts, expedite the testing and refinement of its innovative technologies, and ultimately bring its groundbreaking solutions to market. This funding round marks a significant milestone for Mesosil as it continues to push the boundaries of medical innovation and make a meaningful impact in improving healthcare outcomes. With this new financial backing, Mesosil is well-positioned to drive forward its mission of revolutionizing the medical and dental sectors with groundbreaking advancements in infection treatment and disease prediction.












